Industry News

Pharmaceutical Industry News

As the annual U.S. Conference on…

September 4th, 2025|Fierce Pharma|

As the annual U.S. Conference on HIV/AIDS kicks off in Washington, D.C., this week with a focus on aging with HIV, Gilead Sciences is rolling out a corresponding awareness campaign spotlighting several firsthand stories of

Health and Human Services Seretary…

September 4th, 2025|Fierce Pharma|

Health and Human Services Seretary Robert F. Kennedy Jr. has selected seven new experts that he plans to nominate to the Advisory Committee on Immunization Practices, the panel that issues recommendations on vaccine use in

Novartis is tapping into Argo’s…

September 4th, 2025|Fierce Pharma|

Novartis is tapping into Argo's siRNA capabilities again in a deal worth up to $5.2 billion. The FDA approved a subcutaneous version of Eisai and Biogen's Leqembi. The Hong Kong Stock Exchange issued sanctions against

Citing a “new evidenced based…

September 4th, 2025|Fierce Pharma|

Citing a “new evidenced based philosophy,” the FDA’s Center for Biologics Evaluation and Research is preparing to take a hard line against the common practice of administering certain respiratory virus vaccines at the same time.

The FDA issued a warning letter to…

September 4th, 2025|Fierce Pharma|

The FDA issued a warning letter to Amneal Pharmaceuticals criticizing the drugmaker for failing to correct problems that led to a string of recalls of its generic vancomycin and ropivacaine hydrochloride products.

ImmunoPrecise Antibodies has…

September 4th, 2025|Fierce Pharma|

ImmunoPrecise Antibodies has cemented a recent shift in its focus by adopting a new name: MindWalk. The new brand, which also covers the company’s BioStrand and Talem subsidiaries, is designed to convey the increased focus

A new awareness-raising effort…

September 3rd, 2025|Fierce Pharma|

A new awareness-raising effort from Incyte is aimed at giving doctors an up-close look at the emotional and physical challenges their patients with hidradenitis suppurativa face.

Ori Biotech has lassoed a…

September 3rd, 2025|Fierce Pharma|

Ori Biotech has lassoed a significant milestone for its cell and gene therapy manufacturing platform, IRO, which now boasts a coveted Advanced Manufacturing Technology designation from the FDA.

After joining multiple other…

September 3rd, 2025|Fierce Pharma|

After joining multiple other drugmakers on the U.S. investment bandwagon earlier this year, Gilead Sciences is providing further details on where it plans to channel its $32 billion pledge.

The drug manufacturer lobby’s…

September 3rd, 2025|Fierce Pharma|

The drug manufacturer lobby's seven-figure campaign, set to run through the end of the year, portrays fictional nonprofit hospital leaders celebrating profits derived from the program's discounts.

The move forms the next step in…

September 3rd, 2025|Fierce Pharma|

The move forms the next step in the company's long-held plan to exit manufacturing operations in India, with its Bangalore site expected to cease operations over the 2025-2026 Indian fiscal year.

The UK is losing business…

September 3rd, 2025|Fierce Pharma|

The UK is losing business opportunities in the life sciences sector because the government undervalues the economic and social benefits of investing in the manufacturing of innovative medicines, according to a report from the Cambridge

Paul Offit, M.D., a prominent…

September 3rd, 2025|Fierce Pharma|

Paul Offit, M.D., a prominent vaccine expert who has also become a vocal critic of HHS secretary Robert F. Kennedy Jr., can no longer participate on the FDA’s Vaccines and Related Biological Products Advisory Committee

BD is putting a fresh spin on an…

September 3rd, 2025|Fierce Pharma|

BD is putting a fresh spin on an old awareness drive, returning to the 12-year-old “Love Your Limbs” campaign to mark Peripheral Artery Disease Awareness Month.

The “Check for Cancer”…

September 2nd, 2025|Fierce Pharma|

The “Check for Cancer” campaign, which launched Wednesday, connects the common checkerboard pattern to the concept of undergoing regular cancer screenings.